AG0038GD

745-65-3 | (11α,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid

AG0038GD

SDS

COA

Price

$0.00

Add to Cart

Buy Now

WARNING This product is not for human or veterinary use.

CAS Number	745-65-3
Catalog Number	AG0038GD(AGN-PC-0WAEXH)
Chemical Name	(11α,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid
EC Number	212-017-2
IUPAC Name	7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid
InChI	InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h12-13,15-17,19,21,23H,2-11,14H2,1H3,(H,24,25)/b13-12+/t15-,16+,17+,19+/m0/s1
InChI Key	GMVPRGQOIOIIMI-DWKJAMRDSA-N
MDL Number	MFCD00077860
Molecular Formula	C20H34O5
Molecular Weight	354.4810
SMILES	O[C@@H]1CC([C@H](CCCCCCC(=O)O)[C@H]1\C=C\[C@H](CCCCC)O)=O
UNII	F5TD010360
Synonyms	Alprostadil, Caverject, Edex, Lipo PGE1, Lipo-PGE1, Minprog, Muse, PGE1, PGE1alpha, Prostaglandin E1, Prostaglandin E1alpha, Prostavasin, Prostin VR, Prostine VR, Sugiran, Vasaprostan, Viridal, alprostadil, Prostaglandin E1, 745-65-3, PGE1, Caverject, Edex, Muse, Prostin VR, Alprostadilum, Femprox, Befar, Liprostin, Prostandin, Vitaros, PGE-1, Befar (TN), Prink (TN), Prostavasin, Topiglan, Vasaprostan, Alprostadil(Caverject), Alprox-TD, Prostaglandin-E1, l-Prostaglandin E1, MR-256, Minprog, UNII-F5TD010360, (11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid, CHEMBL495, Prostin VR Pediatric, Lipoprost, Prostivas, Alista, Prink, 11alpha,15alpha-Dihydroxy-9-oxo-13-trans-prostenoic acid, (13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate, CHEBI:15544, PGE1alpha, 9-oxo-11R,15S-dihydroxy-13E-prostaenoic acid, GMVPRGQOIOIIMI-DWKJAMRDSA-N, U-10136, 7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid, F5TD010360, (-)-Protaglandin E1, Sugiran, Viridal, (13E,15S)-11alpha,15-dihydroxy-9-oxoprost-13-en-1-oic acid, l-PGE1, Alprostadilum [INN-Latin], PGE1 Oligomer, 7-((1R,2R,3R)-3-hydroxy-2-((S,E)-3-hydroxyoct-1-en-1-yl)-5-oxocyclopentyl)heptanoic acid, Alprostadil Prostoglandin E1, Promostan, FemLife, ONO 1608, EINECS 212-017-2, RayVa, Prostaglandine E, Caverject Impulse, NSC 165559, 7-((1R,2R,3R)-3-hydroxy-2-((S,E)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl)heptanoic acid, 7-[(1r,3r)-3-Hydroxy-2-[(1e,3s)-3-Hydroxyoct-1-En-1-Yl]-5-Oxocyclopentyl]heptanoic Acid, CPD000112594, SMR000112594, AI3-62116, U 10136, SR-01000597593, MR 256, Prostin VR pediatric (TN), BML1-F06, 3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentaneheptanoic acid, l-3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentaneheptanoic acid, Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,13E,15S)-, Alprostadil(usan), HEI-507, (1R,2R,3R)-3-Hydroxy-2-((E)-(3S)-3-hydroxy-1-octenyl)-5-oxocyclopentaneheptanoic acid, NCGC00016535-01, 119314-69-1, CAS-745-65-3, Vitaros (TN), (13E)-(15S)-11-alpha,15-dihydroxy-9-oxoprost-13-enoate, Alprostadil [USAN:USP:INN:BAN:JAN], AC1NQXHQ, 11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid, PGE1;Prostaglandin E1, Prestwick2_001018, Prestwick3_001018, U-10,136, DSSTox_CID_2578, Prostaglandin E1, 98+%, DSSTox_RID_76640, DSSTox_GSID_22578, SCHEMBL33317, BSPBio_001175, BSPBio_001488, MLS000758964, MLS001424250, BIDD:GT0747, BPBio1_001293, GTPL1882, Alprostadil (JP17/USP/INN), Cyclopentaneheptanoic acid, 3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-, l-, DTXSID9022578, PGE1, Prostaglandin E1, powder, SYN3025, HMS1361K10, HMS1571K17, HMS1791K10, HMS1989K10, HMS2052L11, HMS2090L08, HMS2098K17, HMS3268I09, HMS3402K10, HMS3648O17, HMS3678N07, HMS3715K17, (11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-enoic acid, BCP01740, EX-A1411, HY-B0131, ZINC3813088, Tox21_110482, 3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoic acid, BDBM50101853, BG0025, LMFA03010134, MFCD00077860, s1508, AKOS015961103, Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11.alpha.,13E,15S)-, AC-6095, BCP9000277, CCG-101188, CS-1905, NC00438, RP17688, IDI1_033958, Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,13E,15S)-, homopolymer, Prostaglandin E1, >=99.0% (TLC), SMP2_000271, NCGC00025234-02, NCGC00025234-03, NCGC00025234-04, NCGC00025234-05, AS-16360, BC205461, K274, SAM001246840, SAM001246845, SAM001247093, AB0014134, AB2000131, 11,15-Dihydroxy-9-oxoprost-13-en-1-oate, AB00514004, B2154, ST50826271, Alprostadil, meets USP testing specifications, A11820, C04741, D00180, Prostaglandin E1, >=98% (HPLC), synthetic, Prostaglandin E1;Edex;Muse;Liprostin;Caverject, AB00514004-06, AB00514004-08, AB00514004_09, 745P653, SR-01000946253, SR-01000597593-1, SR-01000597593-5, SR-01000597593-6, SR-01000946253-1, W-104416, BRD-K52459643-001-06-0, BRD-K52459643-001-10-2, BRD-K52459643-001-17-7, (13E)-(15S)-11,15-dihydroxy-9-oxoprost-13-enoate, (13E)-(15S)-11,15-dihydroxy-9-oxoprost-13-enoic acid, Alprostadil, European Pharmacopoeia (EP) Reference Standard, (13e)-(15s)-11alpha,15-dihydroxy-9-oxoprost-13-enoic acid, (11?,13E,15S)-11,15-Dihydroxy-9-oxo-prost-13-en-1-oic acid, (13E)-(15S)-11-alpha,15-dihydroxy-9-oxoprost-13-enoic acid, 11,15-dihydroxy-9-oxoprost-13-en-1-oic acid (ACD/Name 4.0), 3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoate, Alprostadil, United States Pharmacopeia (USP) Reference Standard, (+)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-Cyclopentaneheptanoate, (+)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-Cyclopentaneheptanoic acid, (-)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-Cyclopentaneheptanoate, (-)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-Cyclopentaneheptanoic acid, (11alpha,12alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid, Prostaglandin E1, synthetic, powder, BioReagent, suitable for cell culture, Cyclopentaneheptanoic acid, 3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-, (-)-, Prostaglandin E1, powder, gamma-irradiated, BioXtra, suitable for cell culture, 7-[5-((1E)(3S)-3-hydroxyoct-1-enyl)(1R,4R,5R)-4-hydroxy-2-oxocyclopentyl]hepta noic acid, XPG, Prostin, ProstaglandinE1, Lipo-alprostadil, Prostine VR, Prostaglandin K1, Caverject (TN), Lipo PGE1, Lipo-PGE1, Prostaglandin E1alpha, Edex (TN), Muse (TN), (-)-Prostaglandin E1, D0I4DQ, D0N2EF, Alprostadil (JP15/USP/INN), FA(20:1(OH2,Ke,cyclo)), Alprostadil [USAN:BAN:INN:JAN], Alprostadil [USAN:INN:BAN:JAN], C20H34O5, (C20-H34-O5)x-, ACN-036193, C20-H34-O5, CID5280723, CS-O-05672, D000527, (11-alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid, Cyclopentaneheptanoic acid, 3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-, ()-, Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11?,13E,15S)-,

Complexity	432
Compound Is Canonicalized	Yes
Covalently-Bonded Unit Count	1
Defined Atom Stereocenter Count	4
Defined Bond Stereocenter Count	1
Exact Mass	354.241g/mol
Formal Charge	0
Heavy Atom Count	25
Hydrogen Bond Acceptor Count	5
Hydrogen Bond Donor Count	3
Isotope Atom Count	0
Molecular Weight	354.487g/mol
Monoisotopic Mass	354.241g/mol
Rotatable Bond Count	13
Topological Polar Surface Area	94.8A^2
Undefined Atom Stereocenter Count	0
Undefined Bond Stereocenter Count	0
XLogP3	3.2

GHS Hazard and Precautionary Statements

Symbol:
Hazard Class	6.1
Hazard statements	H317-H319
Packing Group	Ⅲ
Precautionary statements	P280-P305+P351+P338
UN Code	UN 2811

Certificate of Analysis

Lot Number